Vivactis HM3A attended the European Health Summit on December 8th
The European Health Summit is an annual event organised by the European Business Summits. The focus is on bringing together businesses, policymakers, and academia to debate the key healthcare issues in Europe and beyond.
We joined to get the latest insights from international experts.
Interesting discussion panels, such as:
“Showcasing the power of cross industry collaboration for digital acceleration, innovation and global health“.
As EU institutions discuss new pieces of legislation (such as the EHDS) and ways to enhance coordination on global health topics, this panel session highlighted the value of cross-industry collaboration and shed a light on technology innovation within healthcare.
“Towards a rare disease moonshot: scaling up public and private partnerships to accelerate research“.
95% of the 6,000-7,000 identified rare diseases don’t have an approved therapy. For most of these diseases, research is effectively non-existent. The search for new treatments is thwarted by enormous scientific challenges. At the current pace, it would take over 100 years to develop treatments for all rare conditions.
Public-private partnerships could help pool resources to solve problems more quickly, reduce fragmentation and scale up existing initiatives to make a real difference for patients. That’s why a coalition of partners is joining forces to accelerate research in rare and paediatric diseases and bring new therapies to patients.
More information: https://www.europeanhealthsummit.eu/ehs-2022-programme/